The current status and progress of assessing the efficacy of radiotherapy and #br#
chemotherapy in cervical carcinoma by MRI

HOU Mei-xing; SUN Hong-zan; GUO Qi-yong

Journal of China Clinic Medical Imaging ›› 2016, Vol. 27 ›› Issue (2) : 138-141.

The current status and progress of assessing the efficacy of radiotherapy and #br# chemotherapy in cervical carcinoma by MRI

Author information +

History +

Abstract

Cervical cancer is the most common gynecologic malignancies. Chemoradiotherapy is one of the important therapeutic means of advanced cervical cancer. MRI can provide anatomical information, furthermore, MRI can early assess the efficacy of radiotherapy and chemotherapy before the tumor morphology changes by functional imaging technology. Now the current status and progress in assessing the efficacy of radiotherapy and chemotherapy in cervical carcinoma by MRI were reviewed as follows.

Key words

Cervix neoplasms / Treatment outcome / Magnetic resonance imaging

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

HOU Mei-xing, SUN Hong-zan, GUO Qi-yong. The current status and progress of assessing the efficacy of radiotherapy and #br# chemotherapy in cervical carcinoma by MRI[J]. Journal of China Clinic Medical Imaging. 2016, 27(2): 138-141

References

[1]Engin G. Cervical cancer: MR imaging findings before, during, and after radiation therapy[J]. Eur Radiol, 2006, 16(2): 313-324.
[2]Takekumaa M, Hirashima Y, Ito K, et al. Phase Ⅱ trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: A Kansai Clinical Oncology Group study[J]. Gynecol Oncol, 2012, 126(3): 341-345.
[3]Flueckiger F, Ebner F, Poschauko H, et al. Cervical cancer: serial MR imaging before and after primary radiation therapy a 2 year follow up study[J]. Radiology, 1992, 184(1): 89-93.
[4]Gong QY, Brunt JN, Romaniuk CS, et al. Contrast enhanced dynamic MRI of cervical carcinoma during radiotherapy: early prediction of tumour regression rate[J]. Br J Radiol, 1999, 72(864): 1177-1184.
[5]Yuh WT, Mayr NA, Jarjoura D, et al. Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer[J]. Invest Radiol, 2009, 44(6): 343-350.
[6]Mayr NA, Huang Z, Wang JZ, et al. Characterizing tumor heterogeneity with functional imaging and quantifying high-risk tumor volume for early prediction of treatment outcome: cervical cancer as a model[J]. Int J Radiat Oncol Biol Phys, 2012, 83(3): 972-979.
[7]Boss EA, assuger LF, Pop LA, et al. Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinoma[J]. J Magn Reson Imaging, 2001, 13(4): 600-606.
[8]Ellingsen C, Egeland TA, Gulliksrud K, et al. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging[J]. Int J Radiat Oncol Biol Phys, 2009, 73(3): 838-845.
[9]Rofstad EK, Sundfor K, Lyng H, et al. 1Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis[J]. Br J Cancer, 2000, 83(3): 354-359.
[10]Andersen EK, Kristensen GB, Lyng H, et al. Pharmacokinetic analysis and k-means clustering of DCE MR images for radiotherapy outcome prediction of advanced cervical cancers[J]. Acta Oncologica, 2011, 50(6): 859-865.
[11]汪晓红，彭卫军，唐峰，等. T2*磁共振灌注成像监测乳腺癌新辅助化疗疗效的应用研究[J]. 实用放射学杂志，2010，26（9）：1323-1327.
[12]胡文娟，张蓓，潘玉林，等. 磁共振灌注成像对局部进展期乳腺癌新辅助化疗疗效的评价[J]. 放射学实践，2011，26（1）：25-29.
[13]Buekley DL, Robert SC, Paeker GJ, et al. Prostateeaneer: evaluation of vaseular Eharacteristie with dynamic contrast enhaneed TI weighted MR imaging initial experience[J]. Radiology, 2004, 233(3): 709-715.
[14]丁文金，龚光文，周顺科，等. 磁共振灌注成像在宫颈癌诊断及疗效评估价值的初步探讨[J]. 中国医学计算机成像杂志，2012，18（5）：415-418.
[15]Verstraete KL, Deene Y, Roels H, et al. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging-parametric “first-pass” images depict tissue vascularization and perfusion[J]. Radiology, 1994, 192(3): 835-843.
[16]Booth SJ, Pickles MD, Turnbull LW． In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla[J]． BJOG, 2009, 116(2): 300－301．
[17]Mahon MM, Williams AD, Soutter WP, et al. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration[J]. NMR Biomed, 2004, 17(1): 1-9.
[18]Delikatny EJ, Russell P, Hunter JC, et al. Proton MR and human cervical neoplasia: ex vivo spectroscopy allows distinction of invasive carcinoma of the cervix from carcinoma in situ and other preinvasive lesions[J]. Radiology, 1993, 188(3): 791-796.
[19]De Silva SS, Payne GS, Thomas V, et al． Investigation of metabolite changes in the transition from pre-invasive to invasive cervical cancer measured using (1)H and (31)P magic angle spinning MＲS of intact tissue[J]． NMR Biomed, 2009, 22(2): 191－198．
[20]Allen JR, Prost RW, Griffith OW, et al. In vivo proton(HI) magnetic resonance spectroscopy for cervical carcinoma[J]. Am J Clin Oncol, 2001, 24(5): 522-529.
[21]Naganawa S, Sato C, Kumada H, et al. Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix[J]. Eur Radiol, 2005, 15(1): 71-78.
[22]Chen J, Zhang Y, Liang B, et al. The utility of diffusion-weighted MR imaging in cervical cancer[J]. Eur J Radiol, 2010, 74(3): 101-106.
[23]Harry VN, Semple SI, Gilbert FJ, et al. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer[J]. Gynecol Oncol, 2008, 111(2): 213-220.
[24]Liu Y, Bai R, Sun H, et al. Diffusion weighted imaging in predicting and monitoring the response of uterine cervix cancer to concurrent chemoradiation[J]. Clin Radiol, 2009, 64(11): 1067-1074.
[25]Zhang Y, Chen JY, Xie CM, et al. Diffusion-Weighted Magnetic Resonance Imaging for Prediction of Response of Advanced Cervical Cancer to Chemoradiation[J]. J Comput Assist Tomogr, 2011, 35(1): 102-107.
[26]高德宏，沈比先，黄银平，等. MR背景信号抑制弥散加权成像对宫颈癌的诊断与分期价值研究[J]. 医学影像学杂志，2010，20（3）：411-413.